PARSIPPANY, NJ--(Marketwire - April 30, 2009) - The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 4350, the Company issued new inducement stock options to one non-executive new hire due in part to additional hiring in connection with its global expansion.
The inducement stock options covers 3,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent of these options will vest on the date one year from the optionee's hire date, the remainder will vest in monthly increments during the following 36 months (in all cases subject to the terms and conditions of the Company's 2009 Equity Inducement Plan).
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics, The Medicines Company's pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory approval. The Medicines Company's website is www.themedicinescompany.com.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release about The Medicines Company that
are not purely historical, and all other statements that are not purely
historical, may be deemed to be forward-looking statements for purposes of
the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. Without limiting the foregoing, the words "believes,"
"anticipates," "expects" and "estimates" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements involve known and unknown risks and uncertainties that may cause
the Company's actual results, levels of activity, performance or
achievements to be materially different from those expressed or implied by
these forward-looking statements. Important factors that may cause or
contribute to such differences include: whether the Company will be able to
obtain regulatory approvals; whether the Company's products and product
candidates will advance in the clinical trial process on a timely basis or
at all; whether clinical trial results will warrant submission of
applications for regulatory approval; whether physicians, patients and
other key decision-makers will accept clinical trial results; whether the
Company will be able to successfully distribute and market its approved
products; and such other factors as are set forth in the risk factors
detailed from time to time in the Company's periodic reports and
registration statements filed with the Securities and Exchange Commission
including, without limitation, the risk factors detailed in the Company's
Annual Report on Form 10-K filed on March 2, 2009, which are incorporated
herein by reference. The Company specifically disclaims any obligation to
update these forward-looking statements.
